Skip to main content
OpenTrials

Clinical trial condition

Neisseria Meningitidis

Explore clinical trials studying Neisseria Meningitidis. Study availability and eligibility vary by location and protocol.

34 public trials 1 recruiting study
Refine in advanced search Browse all conditions

Neisseria Meningitidis trial results

Completed

Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination

NCT01839175

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Infections, +2 more
Locations
  • Sanofi Pasteur MSD Investigational Site 003 Espoo, Finland
  • Sanofi Pasteur MSD Investigational Site 001 Helsinki, Finland
  • Sanofi Pasteur MSD Investigational Site 002 Helsinki, Finland
  • Sanofi Pasteur MSD Investigational Site 011 Jarvenpaa, Finland
View Trial Details
Completed

Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to ActHIB

NCT00359983

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +5 more
Locations
  • GSK Investigational Site Little Rock, Arkansas, United States
  • GSK Investigational Site Fountain Valley, California, United States
  • GSK Investigational Site Norwich, Connecticut, United States
  • GSK Investigational Site Marietta, Georgia, United States
View all 21 locations
View Trial Details
Completed

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age

NCT00345579

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +5 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Benton, Arkansas, United States
  • GSK Investigational Site Fayetteville, Arkansas, United States
View all 63 locations
View Trial Details
Completed

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.

NCT00345683

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +5 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Benton, Arkansas, United States
  • GSK Investigational Site Jonesboro, Arkansas, United States
View all 57 locations
View Trial Details
Completed

Primary & Booster Study in Infants to Demonstrate Non-inferiority, Persistence & Immunogenicity of Hib-MenC Vaccine

NCT00327184

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +5 more
Locations
  • GSK Investigational Site Espoo, Finland
  • GSK Investigational Site Helsinki, Finland
  • GSK Investigational Site Helsinki, Finland
  • GSK Investigational Site Jarvenpaa, Finland
View all 16 locations
View Trial Details
Completed

Primary & Booster Immunogenicity Study of GSK Biologicals' Hib-MenC Versus a Licensed Men-C Vaccine

NCT00258700

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +5 more
Locations
  • GSK Investigational Site Bydgoszcz, Poland
  • GSK Investigational Site Gdansk, Poland
  • GSK Investigational Site Kielce, Poland
  • GSK Investigational Site Krakow, Poland
View Trial Details
Completed

Safety, Reactogenicity & Immunogenicity Study to Evaluate a Booster Dose of GSK Biologicals' Hib-MenC Given With Priorix™ in Toddlers (13-14 m) Primed With 3 Doses of Hib and MenC-CRM197

NCT00263653

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +5 more
Locations
  • GSK Investigational Site Almería, Spain
  • GSK Investigational Site Almería, Spain
  • GSK Investigational Site Antequera/Málaga, Spain
  • GSK Investigational Site Aravaca, Spain
View all 16 locations
View Trial Details
Completed

Study of a Booster Dose of Hib-MenC Conjugate Vaccine vs Infanrix Hexa When Given to 14 Month Old Subjects

NCT00323050

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +5 more
Locations
  • GSK Investigational Site Alcorcón, Spain
  • GSK Investigational Site Almeira, Spain
  • GSK Investigational Site Barcelona, Spain
  • GSK Investigational Site Barcelona, Spain
View all 16 locations
View Trial Details

Related conditions